Skip to main content
Premium Trial:

Request an Annual Quote

Cerep Inks Kinase-Profiling Agreement with Lilly

NEW YORK (GenomeWeb News) - Cerep today said that it has signed an agreement with Eli Lilly & Co. covering the use of its kinase assay platform to study undisclosed drug targets.

The agreement is an extension of an existing deal between the two companies for access to Cerep's GPCR screening portfolio.

Cerep's kinase profiling service is based on PerkinElmer's Lance Ultra kinase assay technology.

Cerep's kinase platform includes screening capabilities for 250 targets with assays for cancer, cardiac diseases, central nervous system disorders, inflammation, diabetes, metabolic disorders, and other disease states, the company said.

Financial terms of the agreement were not provided.